Curadev proudly launches CRD3874, an innovative allosteric small molecule that uniquely activates the STING pathway without targeting the cGAMP site.

Repare Therapeutics Inc. announced the first patient has been treated in their LIONS Phase 1 trial, focusing on RP-1664 – a leading oral inhibitor targeting polo-like kinase 4, intended for solo therapy.

Nuvig Therapeutics, Inc., initiates first human trial of NVG-2089 for treating inflammatory myopathies and severe autoimmune skin diseases.

Atara Biotherapeutics Reports Filing a New Drug Application for ATA3219 Aimed at Treating Lupus Kidney Inflammation.

CalciMedica has received approval from the FDA to proceed with a Phase 2 study of Auxora™ in treating severe cases of acute kidney injury.

Artax has initiated the dosing of the inaugural participant in their Phase 2a clinical study for Psoriasis, assessing the effects of compound AX-158.

Otsuka Reveals Key Outcomes from Final Stage Trial of AVP-786 for Managing Alzheimer’s-Related Dementia Agitation.

Puma Biotechnology has launched a Phase II study for Alisertib, targeting Small Cell Lung Cancer, named ALISCA-Lung1.

Galderma declares submission approval of Nemolizumab for treating Prurigo Nodularis and Eczema in America and Europe.

Biogen Secures European Commission for New Drug SKYCLARYS® (omaveloxolone), Pioneering Treatment for Friedreich’s Ataxia.

CSL Reveals Key Findings of Phase 3 AEGIS-II Study Assessing Effectiveness and Security of CSL112 (Human Apolipoprotein A-I).

Adverum Biotech Reports Encouraging Initial Results for Safety and Effectiveness in Phase 2 LUNA Study of Ixo-vec for Wet Age-Related Macular Degeneration Patients.